Centers for Disease Control and Prevention. National diabetes statistics report. 2023. Available from: https://www.cdc.gov/diabetes/php/data-research/index.html.

Centers for Disease Control and Prevention. About type 2 diabetes. 2023. Available from: https://www.cdc.gov/diabetes/about/about-type-2-diabetes.html?CDC_AAref_Val=https://www.cdc.gov/diabetes/basics/type2.html.

Lin J, Thompson TJ, Cheng YJ, et al. Projection of the future diabetes burden in the United States through 2060. Popul Health Metr. 2018;16(1):9.

Article  PubMed  PubMed Central  Google Scholar 

Centers for Disease Control and Prevention. Chronic kidney disease. 2022. Available from: https://www.cdc.gov/diabetes/diabetes-complications/diabetes-and-chronic-kidney-disease.html?CDC_AAref_Val=https://www.cdc.gov/diabetes/managing/diabetes-kidney-disease.html.

Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2023. 2023. Available from: https://www.cdc.gov/kidney-disease/php/data-research/?CDC_AAref_Val=https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html.

National Institute for Health and Care Excellence. CVD prevention: chronic kidney disease detection and management. 2024. Available from: https://stpsupport.nice.org.uk/cvd-prevention-ckd/index.html.

Whaley-Connell A, Nistala R, Chaudhary K. The importance of early identification of chronic kidney disease. Mo Med. 2011;108(1):25–8.

PubMed  PubMed Central  Google Scholar 

American Diabetes Association Professional Practice C. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S239–S51.

Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117–S314.

Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1–S127.

Alfego D, Ennis J, Gillespie B, et al. Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database. Diabetes Care. 2021;44(9):2025–32.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan–2022 update. Endocr Pract. 2022;28(10):923–1049.

Article  PubMed  PubMed Central  Google Scholar 

Kidney Disease: Improving Global Outcomes. Chapter 3: Management of progression and complications of CKD. Kidney Int Suppl (2011). 2013;3(1):73–90.

Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–21.

Article  PubMed  CAS  Google Scholar 

Mima A. A narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches. Adv Ther. 2022;39(8):3488–500.

Article  PubMed  Google Scholar 

U.S. Food and Drug Administration. KERENDIA (finerenone) tablets, for oral use. 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215341s001lbl.pdf.

U.S. Food and Drug Administration. INSPRA (eplerenone) tablets, for oral use. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021437s013lbl.pdf.

U.S. Food and Drug Administration. ALDACTONE (spironolactone) tablets for oral use. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012151s075lbl.pdf.

Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. Drug Saf. 2014;37(9):677–92.

Article  PubMed  CAS  Google Scholar 

U.S. Food and Drug Administration. For healthcare professionals: FDA’s examples of drugs that interact with CYP enzymes and transporter systems. 2024. Available from: https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems.

Watson S. Your medicine could spike your potassium. WebMD. 2023. Available from: https://www.webmd.com/a-to-z-guides/medication-affect-potassium-levels.

Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474–84.

Article  PubMed  CAS  Google Scholar 

Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29.

Article  PubMed  CAS  Google Scholar 

Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–63.

Article  PubMed  CAS  Google Scholar 

ClinicalTrials.gov. A study to learn more about how well the study treatment finerenone works, how safe it is, how it moves into, through, and out of the body, and the effects it has on the body when taken with an ACE inhibitor or angiotensin receptor blocker in children with chronic kidney disease and proteinuria (FIONA). 2024. Available from: https://clinicaltrials.gov/study/NCT05196035.

ClinicalTrials.gov. A study to learn more about how safe the study treatment finerenone is in long-term use when taken with an ACE inhibitor or angiotensin receptor blocker over 18 months of use in children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria (FIONA OLE). 2024. Available from: https://clinicaltrials.gov/study/NCT05457283.

ClinicalTrials.gov. Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) & mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40% (FINEARTS-HF). 2024. Available from: https://clinicaltrials.gov/study/NCT04435626.

Solomon SD, Ostrominski JW, Vaduganathan M, et al. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial. Eur J Heart Fail. 2024;26(6):1334–46.

Article  PubMed  CAS  Google Scholar 

ClinicalTrials.gov. A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease (FIND-CKD). 2024. Available from: https://clinicaltrials.gov/study/NCT05047263.

Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL, Sarafidis PA, Tuttle KR, Wanner C, Brinker MD, Dizayee S, Kolkhof P, Schloemer P, Vesterinen P, Perkovic V. FIND-CKD investigators. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrol Dial Transplant. 2025;40(2):308–319. https://doi.org/10.1093/ndt/gfae132.

ClinicalTrials.gov. A study to learn how well the study treatment finerenone works and how safe it is in people with long-term decrease in the kidneys' ability to work properly (chronic kidney disease) together with type 1 diabetes (FINE-ONE). 2024. Available from: https://www.clinicaltrials.gov/study/NCT05901831.

Zhang RM. Single institution prescribing pattern of finerenone in patients with type 2 diabetes and/or chronic kidney disease in the USA. Clin Kidney J. 2023;16(9):1538–9.

Article  PubMed  PubMed Central  Google Scholar 

Sperati CJ, Soman S, Agrawal V, et al. Primary care physicians’ perceptions of barriers and facilitators to management of chronic kidney disease: a mixed methods study. PLoS One. 2019;14(8):e0221325.

Article  CAS  Google Scholar 

Kelepouris E, St Peter W, Neumiller JJ, Wright EE. Optimizing multidisciplinary care of patients with chronic kidney disease and type 2 diabetes mellitus. Diabetes Ther. 2023;14(7):1111–36.

Article  PubMed  PubMed Central  Google Scholar 

Powers MA, Bardsley JK, Cypress M, et al. Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Educ. 2020;46(4):350–69.

Article  PubMed  Google Scholar 

Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care. 2015;38(7):1372–82.

Article  PubMed  Google Scholar 

Martin AL, Warren JP, Lipman RD. The landscape for diabetes education: results of the 2012 AADE National Diabetes Education Practice Survey. Diabetes Educ. 2013;39(5):614–22.

Article  PubMed  Google Scholar 

Chu L, Bhogal SK, Lin P, et al. Awareness of diagnosis and treatment of chronic kidney disease in adults with type 2 diabetes (AWARE-CKD in T2D). Can J Diabetes. 2022;46(5):464–72.

Article  PubMed  Google Scholar 

Powell RE, Zaccardi F, Beebe C, et al. Strategies for overcoming therapeutic inertia in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(9):2137–54.

Article  PubMed  CAS  Google Scholar 

Rodriguez K, Ryan D, Dickinson JK, Phan V. Improving quality outcomes: the value of diabetes care and education specialists. Clin Diabetes. 2022;40(3):356–65.

Article  PubMed  PubMed Central  Google Scholar 

Burke SD, Sherr D, Lipman RD. Partnering with diabetes educators to improve patient outcomes. Diabetes Metab Syndr Obes. 2014;7:45–53.

Article  PubMed  PubMed Central  Google Scholar 

Hoogendoorn CJ, Krause-Steinrauf H, Uschner D, et al. Emotional distress predicts reduced type 2 diabetes treatment adherence in the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2024;47(4):629–37.

Article  PubMed  Google Scholar 

Baah-Nyarkoh E, Alhassan Y, Dwomoh AK, Kretchy IA. Medicated-related burden and adherence in patients with co-morbid type 2 diabetes mellitus and hypertension. Heliyon. 2023;9(4):e15448.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Capoccia K, Odegard PS, Letassy N. Medication adherence with diabetes medication: a systematic review of the literature. Diabetes Educ. 2016;42(1):34–71.

Article  PubMed  Google Scholar 

de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075–90.

Article  PubMed  PubMed Central  Google Scholar 

Gucciardi E, Espin S, Morganti A, Dorado L